Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence


Creese, A; Floyd, K; Alban, A; Guinness, L; (2002) Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet, 359 (9318). pp. 1635-1642. ISSN 0140-6736 DOI: https://doi.org/10.1016/S0140-6736(02)08595-1

Full text not available from this repository. (Request a copy)

Abstract

Background Evidence for cost-effectiveness of interventions for HIV/AIDS in Africa is fragmentary. Cost-effectiveness is, however, highly relevant. African governments face difficult choices in striking the right balance between prevention, treatment, and care, all of which are necessary to deal comprehensively with the epidemic. Reductions in drug prices have raised the priority of treatment, though treatment access is restricted. We assessed the existing cost-effectiveness data and its implications for value-for-money strategies to combat HIV/AIDS in Africa. Methods We undertook a systematic review using databases and consultations with experts. We identified over 60 reports that measured both the cost and effectiveness of HIV/AIDS interventions in Africa. 24 studies met our inclusion criteria and were used to calculate standardised estimates of the cost (US$ for year 2000) per HIV infection prevented and per disability-adjusted life-year (DALY) gained for 31 interventions. Findings Cost-effectiveness varied greatly between interventions. A case of HIV/AIDS can be prevented for $11, and a DALY gained for $1, by selective blood safety measures, and by targeted condom distribution with treatment of sexually transmitted diseases. Single-dose nevirapine and short-course zidovudine for prevention of mother-to-child transmission, voluntary counselling and testing, and tuberculosis treatment, cost under $75 per DALY gained. Other interventions, such as formula feeding for infants, home care programmes, and antiretroviral therapy for adults, cost several thousand dollars per infection prevented, or several hundreds of dollars per DALY gained. Interpretation A strong economic case exists for prioritisation of preventive interventions and tuberculosis treatment. Where potentially exclusive alternatives exist, cost-effectiveness analysis points to an intervention that offers the best value for money. Cost-effectiveness analysis is an essential component of informed debate about priority setting for HIV/AIDS.

Item Type: Article
Keywords: Sub-saharan africa, human-immunodeficiency-virus, child hiv, transmission, rural south-africa, tuberculosis-control, sexual, transmission, infection, health, nevirapine, prevention, AIDS-Related Opportunistic Infections, economics, prevention & control, Acquired Immunodeficiency Syndrome, prevention & control, Africa, Anti-HIV Agents, economics, therapeutic use, Cost-Benefit Analysis, statistics & numerical data, Female, HIV Infections, drug therapy, economics, prevention & control, Health Priorities, Human, Male, Quality-Adjusted Life Years, Tuberculosis, economics, prevention & control
Faculty and Department: Faculty of Public Health and Policy > Dept of Global Health and Development
Research Centre: Social and Mathematical Epidemiology (SaME)
SaME Modelling & Economics
PubMed ID: 12020523
Web of Science ID: 175593300006
URI: http://researchonline.lshtm.ac.uk/id/eprint/17573

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
346Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item